Global Search

Hide Filters

Showing 2892 results

¿Cómo contactar con compras de Novartis?
Comment interagir avec le service Approvisionnement de Novartis?
Pulse Update / Jan 09, 2023

Novartis shares strategy insights and highlights key pipeline catalysts at JP Morgan Healthcare Conference 2023
Statement / Jan 09, 2023

Zolgensma Global Managed Access Program in 2023
Comment facturer Novartis?
¿Cómo facturar a Novartis?
Ad hoc release / Oct 24, 2022

Novartis investigational oral monotherapy iptacopan demonstrates clinically meaningful superiority over anti-C5 treatment in Phase III APPLY-PNH study

Ad hoc announcement pursuant to Art. 53 LRPhase III APPLY-PNH trial met its two primary endpoints for superiority versus anti-C5 treatment in adult paroxysmal nocturnal hemoglobinuria (PNH) patients…
Press release / Oct 14, 2022

Novartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer

Phase III VISION trial showed Pluvicto® plus best standard of care significantly improved survival for patients with pre-treated PSMA-positive mCRPC1 Approximately 473,000 prostate cancer cases and…
Press release / Sep 22, 2022

Novartis unveils new focused strategy, underpinned by eight potential multi-billion dollar peak sales brands & deep pipeline, at Meet the Management event

Transformation to pure-play Innovative Medicines company nears completion Focusing strategy on five core Therapeutic Areas, key technology platforms, and the US Advancing eight in-…
Ad hoc release / Sep 21, 2022

Novartis plans to petition the U.S. Supreme Court to uphold validity of the Gilenya® (fingolimod) dosing regimen patent

Ad hoc announcement pursuant to Art. 53 LR Basel, 21 September, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) has denied its…